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Abstract 
Introduction: Atherosclerotic cardiovascular disease (ASCVD) is a major health problem that 
requires new therapeutic strategies. Cytochrome P450 (CYP) enzymes metabolize arachidonic 
acid to form epoxyeicosatrienoic acids (EETs), which exhibit cardioprotective effects in 
preclinical models. CYP-derived EETs are rapidly hydrolyzed by soluble epoxide hydrolase 
(sEH) into less active dihydroxyeicosatrienoic acids (DHETs). Inhibition of sEH has been 
proposed as a novel ASCVD treatment. However, the relationship between EET concentrations 
and ASCVD prognosis in humans has not been fully investigated. The purpose of this study was 
to evaluate the relationship between EETs and risk of future major adverse cardiovascular 
events (MACE). 
Methods: A secondary analysis was conducted on an existing cohort of 162 participants that 
underwent coronary angiography from 2012 to 2014. Plasma EET and DHET metabolite 
concentrations were quantified by liquid chromatography tandem mass spectrometry. The 
occurrence of MACE (defined as death, acute coronary syndromes [ACS], ischemic stroke or a 
revascularization procedure) was retrospectively collected from the electronic health record. The 
time to MACE or last follow-up from the initial catheterization lab visit was calculated. In 
participants with available follow-up data and angiographic evidence of ASCVD at baseline (N 
equals 98), the relationship between baseline plasma EET concentrations (as well as sum EETs 
plus DHETs [a biomarker of CYP function] and 14,15-EET to DHET ratio [a biomarker of sEH 
function]), and risk of future MACE was evaluated using proportional hazards regression. These 
relationships were examined across low, medium, and high tertiles for each biomarker of 
interest. The analyses were adjusted for covariates that were associated with EET 
concentrations and/or ASCVD outcomes. Data are presented as percentages, median 
[interquartile range], or adjusted hazard ratio (HR) [95 percent confidence interval (CI)]. A p-
value of less than 0.05 was considered statistically significant. 
Results: The ASCVD study population, on average, was 65 years old, 42 percent female, 16 
percent African-American, and 49 percent had a prior revascularization procedure. During a 
median follow-up of 3.8 years, 37 participants (38 percent) experienced a MACE. No significant 
difference was observed in baseline plasma EET concentrations across those with (0.61 ng/mL 
[0.52 to 0.71]) versus without (0.66 ng/mL [0.54 to 0.83]) a future MACE (p equals 0.406). 
Similarly, there were no significant differences in either baseline sum EETs plus DHETs (p 
equals 0.363) or 14,15-EET to DHET ratios (p equals 0.641). Compared to participants in the 
high EET concentration tertile group, those in the combined medium and low tertile group 
appeared to have a higher risk of future MACE (27 percent [9 of 33] versus 43 percent [28 of 
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65], respectively; adjusted HR 1.64 [0.78 to 3.80], p equals 0.201). However, the observed trend 
was not statistically significant. A similar association with future MACE risk was observed with 
sum EETs plus DHETs (24 percent versus 45 percent; adjusted HR 1.98 [0.90 to 4.87], p equals 
0.094), but not 14,15-EET to DHET ratios (38 percent versus 36 percent; adjusted HR 0.94 
[0.44 to 1.91], p equals 0.866). 
Conclusions: No statistically significant associations were found between baseline plasma EET 
metabolite concentrations and the risk of future MACE. Compared to participants in the high 
tertile group, those in the low or medium EET and sum EETs plus DHETs tertiles may have a 
higher risk of future MACE; however, these findings were not statistically significant and should 
therefore be interpreted with caution. If a relationship between EET concentrations and 
occurrence of future MACE exists, the data suggests this may be attributed to lower CYP 
function rather than higher sEH function. Additional investigation in a larger population is 
warranted. 
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Introduction 
Atherosclerotic cardiovascular disease (ASCVD) is a major public health problem in the 
United States. An estimated 16.5 million Americans ≥ 20 years old have ASCVD1. 
Cardiovascular disease including ASCVD is one of the leading causes of death globally (31% of 
all deaths) and in the United States1. Major adverse cardiovascular events (MACE) associated 
with ASCVD include death, acute coronary syndrome (ACS), ischemic stroke, and progressive 
disease requiring a coronary artery revascularization procedure (revasc) such as percutaneous 
coronary intervention (PCI) with stenting or coronary artery bypass graft (CABG) surgery. 
Despite current therapies, patients with ASCVD are still at high risk of experiencing MACE and 
having increased morbidity and mortality resulting from those events. Thus, new treatment 
strategies are needed to improve the prognosis in ASCVD patients by decreasing the incidence 
of MACE and reducing the morbidity and mortality of ASCVD. 
 Precision medicine consists of treatment strategies that are based off of the individual 
variability of patients2. This approach to therapy has already been successful in targeting novel 
therapies to distinct oncogenic mechanisms2 for cancer treatment, but it has not been as largely 
utilized in the cardiovascular field. People at high risk of a detrimental cardiovascular outcome 
with dysfunctions in bioactive pathways could be identified; then biomarkers of these pathways 
could be used to determine which population subsets are at high risk of a detrimental outcome, 
which may be lessened by a therapy that targets the bioactive pathway. Candidate pathways 
are needed for a precision therapy strategy in ASCVD3. Research needs to be done to discover 
populations that will benefit from the development of precision medicine strategies in order to 
improve prognosis of ASCVD.  
 It is well established that cyclooxygenase (COX)- and lipoxygenase (LOX)- mediated 
metabolism of arachidonic acid to bioactive prostaglandin and leukotriene metabolites, 
respectively, is important in the regulation of cardiovascular function4,5. Compared to these well-
known pathways, arachidonic acid metabolism by cytochrome P450 (CYP) enzymes into 
bioactive epoxyeicosatrienoic acids (EETs) has emerged as a novel regulator of cardiovascular 
function and potential therapeutic target for ASCVD. CYP-derived EETs have been shown to 
have potent cardiovascular protective effects including vasodilation and inhibition of myocardial 
and vascular inflammatory responses in preclinical models4-10. However, EETs are rapidly 
metabolized by soluble epoxide hydrolase (sEH) into less active dihydroxyeicosatrienoic acid 
(DHET) metabolites4. Inhibition of sEH increases cellular and circulating EET concentrations, 
promotes the biological effects of EETs, and has demonstrated potent cardiovascular protective 
effects in preclinical models of hypertension, vascular injury, atherosclerosis, and myocardial 
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ischemia-reperfusion injury11-14. Based on these models, sEH inhibition has been proposed15 as 
a potential cardiovascular protective strategy in humans that could potentially benefit from a 
precision medicine approach. 
 Despite the ongoing preclinical and clinical development of sEH inhibitors for non-
ASCVD indications16,17, there is limited knowledge of the relevance of the CYP epoxygenase 
pathway of arachidonic acid metabolism in human ASCVD. Our research team and others have 
previously demonstrated that genetic polymorphisms in CYP epoxygenases and sEH are 
associated with the development of ASCVD, and low circulating EET levels are associated with 
the presence and extent of ASCVD in patients undergoing coronary angiography18-22. However, 
the relationship between EET levels and occurrence of future cardiovascular events in ASCVD 
patients has never been evaluated.  
 Therefore, the objectives of this study were to define the incidence of MACE in an 
established cohort of ASCVD patients with existing eicosanoid metabolite data22, and evaluate 
the relationship between EET metabolite concentrations at baseline and risk of future MACE. 
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Methods 
Study population 
 A cohort of 162 participants 18-80 years of age that underwent a coronary angiography 
procedure at the University of North Carolina (UNC) cardiac catheterization laboratory were 
identified as described22 from September 2012 to February 2014. The exclusion criteria for this 
previously established cohort were severe concurrent illness, systemic inflammatory disease, 
cancer actively being treated, hematologic disorders affecting platelet function, prior heart 
transplantation, hematocrit <30%, ST segment elevation myocardial infarction (STEMI), end-
stage liver disease, end-stage renal disease on dialysis, and systemic immunosuppressive 
medication use (i.e. corticosteroid use).  
 Whole blood was drawn from an indwelling arterial catheter during the coronary 
angiography procedure, but before initiation of a PCI procedure (if indicated). The plasma was 
separated immediately by centrifugation and then stored at a temperature of -80°C. The study 
protocol was approved by the UNC Biomedical Institutional Review Board and eligible 
participants provided written informed consent. 
 
Quantification of eicosanoid metabolite concentrations 
Arterial plasma samples were previously analyzed for eicosanoid metabolites by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) as described22. Data were generated 
for 28 metabolites of interest, including arachidonic acid (AA)-derived CYP epoxides (EETs) and 
AA-derived sEH diols (DHETs). The AA-CYP epoxide metabolites of particular interest are 
regioisomers 14,15-EET, 11,12-EET, and 8,9-EET (the 5,6-EET regioisomer is unstable and not 
quantifiable22). The AA-sEH diols of interest are regioisomers 14,15-DHET, 11,12-DHET, 8,9-
DHET, and 5,6-DHET. Additional metabolites, including AA-derived CYP hydroxyls, AA-derived 
LOX metabolites, AA-derived COX metabolites, linoleic acid (LA)- derived LOX metabolites, LA-
derived CYP epoxides, LA-derived sEH diols, and eicosapentaenoic acid 
(EPA)/docosahexaenoic acid (DHA)- derived epoxide/diols, are also quantified on the panel. 
 Three CYP epoxygenase pathway biomarkers were calculated for each participant: sum 
EETs, sum EETs + DHETs, and 14,15-EET:DHET ratio, as previously described21,22,27. In order 
to calculate the sum total concentration of EETs, the 14,15-EET, 11,12-EET, and 8,9-EET 
metabolites, which exhibit high inter-metabolite correlations, were summed for each participant 
to calculate the total EET concentration (sum EETs). This variable is reflective of the total 
circulating EET concentration in each individual participant. The sum EETs + DHETs were 
calculated by adding the 14,15-EET, 11,12-EET, 8,9-EET, 14,15-DHET, 11,12-DHET, 8,9-
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DHET, and 5,6-DHET metabolites in each participant. This represents CYP epoxygenase 
function because CYP epoxygenases convert arachidonic acid into EET metabolites which are 
then converted into DHETs by sEH4,5 (Supplemental Figure 1).  In order to calculate the 14,15-
EET:DHET ratio, the metabolite 14,15-EET was divided by the metabolite 14,15-DHET for each 
participant. This ratio is a biomarker of sEH activity because EET metabolites are converted to 
DHETs by sEH4 and 14,15-EET is the preferred substrate for sEH5 (Supplemental Figure 1).   
 
Collection of clinical outcome data from the electronic health record 
 The electronic health record (EPIC) was retrospectively evaluated to identify 
hospitalizations for up to 4 years of follow-up after the participant’s initial visit for the coronary 
angiography procedure (baseline). Twenty-one participants did not have a follow-up visit in the 
electronic health record, were considered lost to follow-up, and were excluded from the outcome 
analysis.  
MACE + revasc was defined as a composite outcome of death from any cause, 
hospitalization due to non-fatal acute coronary syndrome [ACS] (unstable angina [UA], non-ST 
elevation myocardial infarction [NSTEMI], or ST-elevated myocardial infarction [STEMI]), 
hospitalization due to a non-fatal cerebrovascular event (ischemic stroke or transient ischemic 
attack [TIA]), or hospitalization due to a coronary artery revascularization procedure including 
percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]. All 
potential events were verified by at least 2 individuals. The date of each event was recorded as 
well as the date of the last follow-up visit as shown in the electronic health record. In individuals 
without an event, follow-up was censored at the last available encounter in the medical record 
during 4 years of follow-up. 
 
Statistical analysis 
Data are presented as a mean ± standard deviation, median (interquartile range [IQR]), 
or count (%) unless otherwise indicated. Prior to analysis, metabolite concentrations and EET: 
DHET ratios were log transformed because the data were not normally distributed. Statistical 
analyses were performed using JMP Pro 12. A p-value < 0.05 was considered to be statistically 
significant.  
The number and frequency of participants that experienced a MACE + revasc event over 
the 4-year follow-up period was calculated in the cohort of 141 participants with follow-up data in 
the electronic health record.  The median (interquartile range) for the time to MACE + revasc or 
last follow-up from the initial catheterization lab visit, and the number and frequency of each 
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individual component of the MACE + revasc composite were also calculated for each 
participant.  
Demographic and clinical factors were collected from the participants as previously 
described22. This included variables such as demographic factors (gender, race, age), 
comorbidities and risk factors for ASCVD (cigarette smoking status, diabetes, hypertension, 
hyperlipidemia, prior cardiovascular events, obese BMI), and indicators of existing ASCVD 
(maximum coronary artery stenosis, prior revascularization procedure). The number and 
frequency of each clinical and demographic factor was reported for the cohort of 141 
participants. Then, those participants were further stratified into those with (N=98) and without 
(N=43) significant ASCVD at baseline (defined as having current ≥ 50% stenosis or a prior 
revascularization procedure in a major coronary artery). The number and frequency of each 
demographic and clinical variable was also reported within the significant ASCVD strata.  
 Study population characteristics were compared across those with and without a MACE 
+ revasc event using a student’s t-test for continuous data and chi-squared or Fisher’s exact 
test for categorical data as appropriate. Since 37 of the 41 MACE + revasc events that were 
identified occurred in the strata of patients with significant ASCVD at baseline (N=98), we 
performed all further described analyses in this population. 
Sum EETs, sum EETs + DHETs, and 14,15-EET:DHET ratios (log-transformed) were 
compared across those with and without a future MACE + revasc event using a student’s t-test. 
Sum EETs was the primary eicosanoid metabolite endpoint, while the sum EETs + DHETs and 
the 14,15-EET:DHET ratio were secondary endpoints. Each biomarker was then divided into 
tertiles, which were classified as low, medium, and high. Participant characteristics were 
compared across the tertiles to determine if confounding variables existed between the groups 
using an analysis of variance for continuous data and chi-squared or Fisher’s exact test for 
categorical data as appropriate. The relationship between tertiles and time to occurrence of a 
future MACE + revasc event was assessed using Cox proportional hazards regression. The 
hazard ratio (HR) and 95% confidence intervals (CIs), relative to the low tertile, were calculated 
for each biomarker. As a secondary analysis, the low and medium (referred to as low/med) 
tertiles were combined and the relationship between that new group and the high tertile group 
was determined using Cox proportional hazards regression. Kaplan-Meier curves were 
generated using GraphPad Prism 7. 
The relationship between demographic and clinical factors and the occurrence of future 
MACE + revasc events was assessed using Cox proportional hazards regression. The variables 
identified that were associated with EET concentrations and/or ASCVD outcomes were used to 
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create a multivariable adjusted model for the analyses described above. The model adjusted for 
demographic characteristics (age, race, sex) and confounding variables (history of diabetes, 
history of hypertension, prior revascularization procedure, current obstructive ASCVD, history of 
smoking, and obesity) that were associated with EET concentrations and/or ASCVD outcomes. 
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Results 
Study population 
 The baseline characteristics of participants in this study are shown in Table 1. In the 
participants with follow-up (N=141), 98 (70%) exhibited significant ASCVD at the time of the 
baseline cardiac catheterization. The age median for the ASCVD population was 65 (53-71) 
years old with 42% being male and 16% being African American. Some of the risk factors for 
ASCVD that participants had were hypertension (80%), hyperlipidemia (68%), and prior 
revascularization (49%) indicating progressive disease. A comparison of clinical and 
demographic factors across participants with and without a future MACE + revasc event is 
shown in Supplemental Table 1. Notably, participants with a prior revascularization procedures 
were significantly more likely to experience a future MACE + revasc event (p=0.014).  
 
Incidence of MACE + revasc in the study population 
 In Table 2, the incidence of events over the 4-year follow-up period is shown in the 
entire study population with follow-up data (N=141) and the strata of participants with significant 
ASCVD at baseline (N=98). Out of the 41 events that occurred in the follow-up population 
(N=141), 37 (90%) of those occurred within the ASCVD population (2 deaths, 11 non-fatal ACS 
events, 3 non-fatal stroke/TIA events, and 21 revascularization procedures). Overall, the 
percentage of participants who had a MACE + revasc event in the ASCVD population was 
37.8%. The majority of events that occurred were revascularization procedures.  The median 
(IQR) time to MACE + revasc or last follow-up in the ASCVD population was 2.5 (0.8-3.9) years. 
 
Comparison of clinical factors across eicosanoid metabolite tertiles 
 Comparisons of clinical factors across sum EETs tertiles were completed to determine 
whether the data was affected by any confounding variables (Table 3). The age of the 
participants (p=0.025), obesity status (p=0.039), smoking status (p=0.039), and ACS upon 
presentation to the catheterization lab (p=0.028) differed significantly between the tertiles. 
Participants in the low tertile tended to be younger and more obese than the participants in the 
medium and high tertiles. More participants had a recent smoking history in the medium tertile 
compared to the low and high tertiles. Participants who presented to the lab with ACS events 
were mostly in the low and high groups as compared to the medium tertile group, respectively. 
Secondary comparisons across tertiles were performed in the sum EETs + DHETs tertiles 
(Supplemental Table 2) and 14,15-EET:DHET ratio tertiles (Supplemental Table 3). No 
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clinical factors were significantly different across sum EETs + DHETs, but age was significantly 
different across the 14,15-EET:DHET ratio tertiles. 
 
Comparison of eicosanoid metabolites across future MACE + revasc event status 
Within the ASCVD population, no significant differences in sum EETs, sum EETs + 
DHETs, or 14,15-EET:DHET ratio concentrations at baseline were observed between 
participants that experienced a future MACE + revasc event versus those that did not (Table 4).  
 Sum EET concentration tertiles at baseline were not significantly associated with 
incidence of a MACE + revasc event (log rank p=0.279) (Figure 1). As compared to the high 
sum EETs tertile event rate (27%), the risk of experiencing a MACE + revasc event in the low 
sum EETs tertile group (39%) (adjusted HR 1.32, 95% CI 0.53-3.39, p=0.553) and the medium 
sum EETs tertile group (47%) (adjusted HR 2.03, 95% CI 0.85-5.10, p=0.110) was not 
statistically significant. The low/med group event rate of 43% as compared to the high sum 
EETs tertile event rate (adjusted HR 1.64, 95% CI 0.78-3.80, p=0.201) was not statistically 
significant as well.  
There appeared to be a trend toward a higher incidence of future MACE + revasc events 
in the medium and low sum EETs + DHETs tertiles compared to the high tertile (log rank 
p=0.313) (Figure 2A). Compared to the high sum EETs + DHETs tertile event rate (24%), the 
participants in the low tertile (36%) (adjusted HR 1.51, 95% CI 0.58-4.08, p=0.400) and the 
medium tertile (53%) (adjusted HR 2.58, 95% CI 1.05-6.82, p=0.038) appeared to be at higher 
risk of a MACE + revasc event, although the low tertile comparison was not significant. The 
participants in the low/med sum EETs + DHETs group also appeared to have a higher event 
rate (45%) than the high tertile group (adjusted HR 1.98, 95% CI 0.90-4.87, p=0.094). There 
was no association between 14,15-EET:DHET ratio tertiles and incidence of future MACE + 
revasc events (log rank p=0.593) (Figure 2B).  
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Discussion 
CYP-derived EETs have been shown to have potent protective effects in preclinical 
models4-10 and low circulating concentrations have been associated with the presence of 
significant ASCVD22. However, the relationship between EETs and prognosis of ASCVD has 
never been evaluated and remains unclear. The analysis did not demonstrate any statistically 
significant associations between eicosanoid metabolite concentrations at baseline and future 
MACE + revasc events. Secondary analyses revealed that participants in low/medium sum 
EETs and sum EETs + DHETs tertiles may exhibit a higher risk of experiencing a future MACE 
+ revasc event. However, the trend observed with sum EETs was not statistically significant, 
and thus, these results should be interpreted with caution. If a relationship between EETs and 
occurrence of MACE + revasc events exists, these data suggest the observed association 
between lower plasma EET concentrations and higher risk of MACE + revasc events may be 
attributed to lower CYP epoxygenase function rather than higher sEH function. 
 It is well-established that CYP-derived EETs exhibit potent anti-inflammatory effects 
through lessening of endothelial activation and leukocyte adhesion via nuclear factor kappa B 
(NF-κB) inhibition6.7, and exhibit potent vasodilatory properties through activation of Ca2+-
sensitive K+ channels (BKCa) resulting in hyperpolarization8. EETs also stimulate endothelial cell 
growth and survival via activation of phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) 
signaling9, as well as reduce ischemia/reperfusion injury of the myocardium by a variety of 
mechanisms10. Increasing EET levels by inhibition of sEH has shown antihypertensive 
effects11,12, renal protective effects11,13, and cardiac protective effects14 in multiple preclinical 
models of cardiovascular disease, including ischemia-reperfusion injury, by promoting the anti-
inflammatory, vasodilatory and cellular protective properties of EETs. Although there is 
substantial preclinical evidence supporting the cardiovascular protective effects of EETs, these 
effects in human models of ASCVD remain poorly understood and require further study. 
 Prior analyses in the current study population revealed that low circulating EETs and 
lower CYP epoxygenase function (lower sum EETs + DHETs) were significantly associated with 
the presence and severity of obstructive ASCVD at baseline; however, in contrast, higher sEH 
function (lower 14,15-EET:DHET ratio) was not associated with severity of ASCVD22. The gene 
encoding sEH, EPHX2, has been shown to have polymorphisms, which can affect sEH 
activity15. Variation in EPHX2 is associated with increased incidence of ASCVD18,23. Notably, the 
gain-of-function polymorphism Lys55Arg is related to higher sEH activity and increased 
incidence of ASCVD18. Variations in the CYP2C9, CYP2C8, and CYP2J2 enzymes that 
metabolize arachidonic acid into EETs have also been associated with varying EET 
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concentrations and cardiovascular disease19-21. This evidence suggests that genetic or 
metabolite biomarkers could identify a target population predisposed to low EET concentrations 
and higher ASCVD risk. The current analysis of future clinical outcomes in this study population 
suggest that lower EET concentrations and lower CYP epoxygenase function may also be 
associated with a worsened prognosis of ASCVD over time. These data suggest that if a 
precision medicine strategy is attempted to target patients with low EETs and significant 
ASCVD, it may be better to target CYP epoxygenase function instead of the sEH enzyme in 
order to increase EET levels. A novel sEH inhibitor is now currently in phase 2 clinical trials for 
COPD16,17,26, but could be considered as a therapy for ASCVD patients. More research will be 
required to determine if an sEH inhibitor may be useful in humans with lower EET levels at 
baseline and significant ASCVD. 
The current study investigated the relationship between EET levels and prognosis of 
human ASCVD for the first time by utilizing a very unique set of preexisting data. Our use of an 
existing cohort of eicosanoid metabolite data, the largest known ASCVD cohort with such data, 
is exceptionally resourceful given the difficulty in quantifying EET and DHET metabolites. 
However, there are multiple limitations in the current study that should be addressed. First. this 
study is observational, and thus it is not possible to determine if EETs alone cause MACE + 
revasc over time. In addition, potential confounding factors that cannot be changed could be 
present and interfere with the relationship between EETs and MACE + revasc. In order to 
lessen the impact of ASCVD status at baseline, which is known to be associated with lower EET 
concentrations and higher risk of MACE + revasc, we conducted analyses primarily within the 
strata of 98 participants with significant ASCVD at baseline.  We also adjusted for additional 
clinical and demographic factors that are predictive of MACE + revasc events and/or EET 
concentrations in future analyses to increase confidence in the observed associations.  
Another limitation of this study is the small sample size which may lead to false positives 
and unreliable results. Larger populations are required to validate results in the future.  Lastly, in 
parallel to the metabolism of arachidonic acid to EETs by CYP2J and CYP2C, the CYP4F and 
CYP4A families metabolize arachidonic acid into 20-hydroxyeicosatraenoic acid (20-HETE)27,28, 
which has vasoconstrictive and pro-inflammatory effects4.  The EET concentrations may not be 
uniquely associated with MACE + revasc events over time as compared to other metabolites 
such as 20-HETE. This can be addressed with future analyses by looking at the available 
metabolite panel as a whole to determine relative associations between other metabolites and 
MACE + revasc.  
A key novel feature of this study is its focus on precision medicine in the cardiovascular 
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field.  While the precision medicine approach to therapy has already been successful in 
targeting novel therapies to distinct oncogenic mechanisms2 for cancer treatment, it has not 
been as largely utilized in treatment of ASCVD. This research helps to elucidate information 
related to the three tested biomarkers (EET concentrations, CYP epoxygenase function, sEH 
activity) prompting new therapeutic approaches for ASCVD patients. The sum EETs + DHETs 
(CYP epoxygenase function) and 14,15-EET:DHET ratio (sEH function) were analyzed to obtain 
insight into an underlying mechanism behind low concentrations of EETs (sum EETs). CYP 
epoxygenase function, rather than sEH function, seem to be the more likely driver behind the 
association between lower EETs and higher risk of MACE + revasc events. If sEH function was 
found to be the driving force behind an association of low EETs and increased future MACE + 
revasc, then sEH inhibitors could be investigated for cardiovascular indications in addition to the 
indications for which they are already being tested. The sEH enzyme has already been utilized 
as a potential therapeutic target for inflammatory diseases16,26, such as COPD, as evidenced by 
phase 2 clinical trials. If CYP epoxygenase activity is found to be the driving force, then this 
could be the focus of future studies as well as more viable therapeutic strategies such as 
structural analogs of EETs29 rather than sEH inhibitors for ASCVD patients predisposed to low 
EET biosynthesis. The relationship between sEH or CYP epoxygenase function and various 
genotypes could be identified and used as indicators for those who may benefit from precision 
medicine for ASCVD.  
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Conclusions 
Despite current therapies, ASCVD is still a major public health problem in the United 
States1. Though we can use genetic testing to diagnose and risk-stratify patients with 
cardiovascular disease, therapeutically targeting populations based on genotyping has not yet 
been utilized in the cardiovascular field3. Candidate pathways for the development of a precision 
medicine strategy in ASCVD are needed3. In this study, a unique cohort with preexisting 
eicosanoid data22 was used to investigate the relationship between EET concentrations and 
ASCVD prognosis. Patients with existing ASCVD, lower EETs, and lower CYP epoxygenase 
function at baseline appeared to have a higher risk of future cardiovascular events. In contrast, 
sEH function was not associated with risk of events over time. Therefore, if a relationship 
between lower EETs and higher risk of future events exists, lower CYP epoxygenase function 
may be the driver instead of higher sEH function. However, these results should be interpreted 
with caution. Ultimately, larger populations will be needed to further investigate the relationship 
between EETs and ASCVD prognosis. The current study sets the stage for future research in 
this field, which may lead to future precision medicine strategies in ASCVD. 
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Tables and Figures 
 
Table 1: Description of the study population 
 
Characteristic Study Population Strata with ASCVD  
at baseline 
N 141 98 
Age (years) 64 (55-70) 65 (53-71) 
Female 64 (45.4%) 41 (41.8%) 
African American race 30 (21.3%) 16 (16.3%) 
BMI (kg/m2) 29.8 (26.6-36.3) 29.9 (27.0-36.1) 
Obese BMI ≥ 30.00 68 (48.2%) 48 (49.0%) 
Current/recent (<1 year) smoker 38 (27.0%) 29 (29.6%) 
Past medical history   
History of hypertension 112 (79.4%) 78 (79.6%) 
History of diabetes 43 (30.5%) 35 (35.7%) 
History of hyperlipidemia  94 (66.7%) 67 (68.4%) 
Current heart failure  20 (14.2%) 14 (14.3%) 
Previous myocardial infarction 22 (15.6%) 22 (22.5%) 
Previous stroke or TIA  15 (10.6%) 12 (12.2%) 
Previous Revascularization 48 (34.0%) 48 (49.0%) 
Prior PCI 37 (26.2%) 37 (37.8%) 
Prior CABG 15 (10.6%) 15 (15.3%) 
Cardiac catheterization lab   
ACS on presentation 26 (18.4%) 25 (25.5%) 
Presence of collateral 20 (14.2%) 20 (20.4%) 
Current obstructive ASCVDa 68 (48.2%) 68 (69.4%) 
Stenosis in most severe vessel (%) 
          Significant ASCVDb 
60 (20-90) 
98 (69.5%) 
80 (50-91) 
98 (100%) 
 
BMI = body mass index, TIA = transient ischemic attack, PCI = percutaneous coronary intervention, 
CABG = coronary artery bypass graft, ACS = acute coronary syndrome 
 
Data presented as median (interquartile range) or count (proportion) 
 
aDefined as a current ≥ 50% stenosis in the left main coronary artery or ≥ 70% stenosis in one or more of 
the non-left main coronary arteries during the index angiography procedure 
 
bDefined as a current ≥ 50% stenosis or prior revascularization (PCI or bypass graft) in a major coronary 
artery 
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Table 2: Incidence of future MACE + revasc over a 4-year time period 
 
MACE = major adverse cardiovascular events, revasc = revascularization procedures, ACS = acute 
coronary syndromes, UA = unstable angina, NSTEMI = non-ST elevated myocardial infarction, TIA = 
transient ischemic attack, PCI = percutaneous coronary intervention, CABG = coronary artery bypass 
graft 
 
Data presented as median (interquartile range) or count (proportion). 
 
 
 
 
 
 
 
 
 
 
 
Variables of Interest Study Population Strata with ASCVD  
at baseline 
N 141 98 
MACE + revasc 41 (29.1%) 37 (37.8%) 
     Death (all cause) 3 (2.1%) 2 (2.0%) 
     Non-fatal ACS 12 (8.5%) 11 (11.2%) 
       UA 2 (1.4%) 2 (2.0%) 
       NSTEMI 10 (7.1%) 9 (9.2%) 
       STEMI 0 0 
     Non-fatal stroke or TIA 4 (2.8%) 3 (3.1%) 
       Stroke 3 (2.1%) 2 (2.0%) 
       TIA 1 (0.7%) 1 (1.0%) 
     Revascularization procedure 21 (14.9%) 21 (21.4%) 
       PCI 18 (12.8%) 18 (18.4%) 
       CABG 3 (2.1%) 3 (3.1%) 
Length of Follow-up (years) 3.8 (2.8-4.0) 3.8 (3.1-4.0) 
Time to MACE + revasc  
or last follow-up (years) 
 
3.2 (1.0-4.0) 2.5 (0.8-3.9) 
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Table 3: Analysis of clinical factors across sum EET tertiles in the 
ASCVD population 
 
Characteristic Low Sum 
EETs 
(N=33) 
Medium Sum 
EETs (N=32) 
High Sum 
EETs 
(N=33) 
p-value 
Age (years) 64 (51.5-68) 67.5 (57.3-
73.8) 
68 (59.5-
71.5) 
p=0.025 
Age > 65 years old 12 (36.4%) 18 (56.3%) 18 (54.6%) p=0.200 
Female 14 (42.4%) 14 (43.8%) 13 (39.4%) p=0.935 
African American race 3 (9.1%) 8 (25.0%) 5 (15.2%) p=0.216 
BMI (kg/m2) 34.7 (28.8-
37.0) 
28.6 (26.0-
34.2) 
29.2 (25.7-
36.5) 
p=0.088 
Obese BMI ≥ 30.00 22 (66.7%) 12 (37.5%) 14 (42.4%) p=0.039 
Current/recent (<1 year) smoker 8 (24.2%) 14 (43.8%) 7 (21.2%) p=0.104 
Past medical history     
History of hypertension 27 (81.8%) 27 (84.4%) 24 (72.7%) p=0.542 
History of diabetes 12 (36.4%) 13 (40.6%) 10 (30.3%) p=0.681 
History of hyperlipidemia 24 (72.7%) 19 (59.4%) 24 (72.7%) p=0.419 
Current heart failure  6 (18.2%) 5 (15.6%) 3 (9.1%) p=0.592 
Previous myocardial 
infarction 
9 (27.3%) 7 (21.9%) 6 (18.2%) p=0.674 
Previous stroke or TIA  6 (18.2%) 4 (12.5%) 2 (6.1%) p=0.323 
Previous Revascularization 21 (63.6%) 12 (37.5%) 15 (45.5%) p=0.094 
Prior PCI 18 (54.6%) 9 (28.1%) 10 (30.3%) p=0.051 
Prior CABG 6 (18.2%) 3 (9.4%) 6 (18.2%) p=0.569 
Cardiac catheterization lab     
ACS on presentation 10 (30.3%) 3 (9.4%) 12 (36.4%) p=0.028 
Presence of collateral 10 (30.3%) 6 (18.8%) 4 (12.1%) p=0.193 
Current obstructive 
ASCVDa 
25 (75.8%) 21 (65.6%) 22 (66.7%) p=0.612 
Stenosis in most severe 
vessel (%) 
 
90 (60-92.5) 75 (50-90) 80 (55-95) p=0.287 
 
BMI = body mass index, TIA = transient ischemic attack, PCI = percutaneous coronary intervention, 
CABG = coronary artery bypass graft, ACS = acute coronary syndrome 
 
Data presented as median (interquartile range) or count (proportion) 
 
aDefined as a current ≥ 50% stenosis in the left main coronary artery or ≥ 70% stenosis in one or more of 
the non-left main coronary arteries 
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Table 4: Comparison of Eicosanoid Metabolites at baseline across future MACE + 
Revasc status in the ASCVD population 
 
Eicosanoid Biomarkers MACE + revasc (yes) 
(N=37) 
MACE + revasc (no) 
(N=61) 
p-value 
Sum EETs (ng/mL) 0.61 (0.52-0.71) 0.66 (0.54-0.83) 0.406 
Sum EETs + DHETs (ng/mL) 2.63 (2.19-3.05) 2.75 (2.12-3.42) 0.363 
14,15-EET:DHET ratio (ng/mL) 0.30 (0.23-0.42) 0.34 (0.25-0.42) 0.641 
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	Figure 1. Sum EET levels at baseline and risk of future MACE + revasc in the ASCVD 
population. Kaplan Meier curves were created for incidence of MACE + revasc for sum EET 
tertiles. The unadjusted log rank p-value for trend across tertiles is shown. Next to the curve, the 
number of events and event rates within each tertile are provided. Adjusted hazards ratios (HR), 
95% confidence intervals (CI), and p-values are shown next to the event rates. The event 
number/rates, HR, 95% CI, and p-values are also reported for the low and medium tertiles 
combined (low/med) to compare against the high tertile.  
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Figure 2. Eicosanoid metabolite levels at baseline and risk of future MACE + revasc in the 
ASCVD population. Kaplan Meier curves were created for incidence of MACE + revasc 
corresponding to tertiles for baseline sum EETs + DHETs (A) and 14,15-EET:DHET ratios (B). 
On each curve, the unadjusted log rank p-value for trend across tertiles is shown. Next to the 
curves, the number of events and event rates within each tertile are provided. Adjusted hazards 
ratios (HR), 95% confidence intervals (CI), and p-values are shown next to the event rates. The 
event number/rates, HR, 95% CI, and p-values are also reported for the low and medium tertiles 
combined (low/med) to compare against the high tertiles.  
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Supplemental Materials 
 
Supplemental Figure 1: Biosynthesis and metabolism of epoxyeicosatrienoic acids (EETs). 
Cytochrome-P450 (CYP) enzymes metabolize arachidonic acid (AA) into bioactive EET 
regioisomers. EETs are then further metabolized into less active dihydroxyeicosatrienoic acid 
(DHETs) regioisomers by soluble epoxide hydrolase (sEH). CYP function is represented by sum 
EETs + DHETs because AA is metabolized by CYPs into EETs and then further metabolized 
into DHETs, and so the sum of EETs + DHETs is a biomarker of downstream effects of CYPs. 
The 14,15-EET:DHET ratio is representative of sEH function because 14,15-EETs are the 
preferred substrate of sEH and 14,15-EET is metabolized by sEH into 14,15-DHET.  
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Supplemental Table 1: Comparison of clinical factors across MACE + revasc event status 
in patients with significant ASCVD 
   
Characteristic MACE + 
revasc (yes) 
(N=37) 
MACE + 
revasc (no) 
(N=61) 
p-value HR (95% CI) p-value 
Age > 65 years old 17 (48.7%) 30 (49.2%) 0.959 1.05 (0.55-2.00) p=0.888 
Female 17 (46.0%) 24 (39.3%) 0.521 1.12 (0.58-2.14) p=0.521 
African American race 6 (16.2%) 10 (16.4%) 0.982 1.04 (0.39-2.32) p=0.982 
Obese BMI ≥ 30.00 19 (51.4%) 29 (47.5%) 0.715 1.09 (0.57-2.10) p=0.715 
Current/recent (<1 year) 
smoker 
14 (37.8%) 15 (24.6%) 0.167 1.33 (0.67-2.56) p=0.167 
Past medical history      
History of hypertension 32 (86.5%) 46 (75.4%) 0.177 1.89 (0.81-5.54) p=0.177 
History of diabetes 16 (43.2%) 19 (31.2%) 0.228 1.54 (0.79-2.95) p=0.228 
History of 
hyperlipidemia 
26 (70.3%) 41 (67.2%) 0.752 1.16 (0.59-2.44) p=0.752 
Current heart failure
  
7 (18.9%) 7 (11.5%) 0.314 1.32 (0.53-2.84) p=0.314 
Previous myocardial 
infarction 
10 (27.0%) 12 (19.7%) 0.401 1.31 (0.60-2.61) p=0.401 
Previous stroke or TIA
  
4 (10.8%) 8 (13.1%) 0.734 0.80 (0.24-2.01) p=0.734 
Previous 
Revascularization 
24 (64.9%) 24 (39.3%) 0.014 2.08 (1.08-4.22) p=0.014 
Prior PCI 19 (51.4%) 18 (29.5%) 0.031 2.06 (1.08-3.97) p=0.031 
Prior CABG 7 (18.9%) 8 (13.1%) 0.444 1.11 (0.45-2.38) p=0.444 
Cardiac catheterization lab      
ACS on presentation 10 (27.0%) 15 (24.6%) 0.789 1.09 (0.51-2.20) p=0.789 
Presence of collateral 7 (18.9%) 13 (21.3%) 0.775 0.94 (0.38-2.00) p=0.775 
Current obstructive 
ASCVDa 
28 (75.7%) 40 (65.6%) 0.288 1.66 (0.81-3.73) p=0.566 
Stenosis in most 
severe vessel (%) 
90 (60-92.5) 80 (50-92.5) 0.224 --------------------- -------- 
 
BMI = body mass index, TIA = transient ischemic attack, PCI = percutaneous coronary intervention, 
CABG = coronary artery bypass graft, ACS = acute coronary syndrome 
 
Data presented as median (interquartile range) or count (proportion) 
 
aCurrent obstructive coronary artery disease (CAD) defined as ≥ 50% stenosis in the left main coronary 
artery or ≥ 70% stenosis in one or more of the non-left main coronary arteries 
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Supplemental Table 2: Analysis of clinical factors across sum EETs + DHETs tertiles in 
the ASCVD population 
 
Characteristic Low Sum 
EETs + 
DHETs 
(N=33) 
Medium Sum 
EETs + 
DHETs 
(N=32) 
High Sum 
EETs + 
DHETs 
(N=33) 
p-value 
Age (years) 65 (52-69) 66 (60-72.8) 65 (54-70.5) p=0.138 
          Age >65 years old 15 (45.5%) 17 (53.1%) 16 (48.5%) p=0.824 
Female 14 (42.4%) 18 (56.3%) 9 (27.3%) p=0.058 
African American race 5 (15.2%) 8 (25.0%) 3 (9.1%) p=0.216 
BMI (kg/m2) 34.4 (28.9-
36.6) 
29.5 (27.0-
37.2) 
27.8 (25.1-
34.0) 
p=0.060 
Obese BMI ≥ 30.00 21 (63.6%) 14 (43.8%) 13 (39.4%) p=0.109 
Current/recent (<1 year) smoker 5 (15.2%) 13 (40.6%) 11 (33.3%) p=0.057 
Past medical history     
History of hypertension 26 (78.8%) 29 (90.6%) 23 (36.7%) p=0.115 
History of diabetes 11 (33.3%) 14 (43.8%) 10 (30.3%) p=0.499 
History of hyperlipidemia 21 (63.6%) 24 (75.0%) 22 (66.7%) p=0.590 
Current heart failure  7 (21.2%) 3 (9.4%) 4 (12.1%) p=0.445 
Previous myocardial 
infarction 
8 (24.2%) 6 (18.8%) 8 (24.2%) p=0.826 
Previous stroke or TIA  5 (15.2%) 3 (9.4%) 4 (12.1%) p=0.926 
Previous Revascularization 18 (54.6%) 15 (46.9%) 15 (45.5%) p=0.730 
Prior PCI 15 (45.5%) 12 (37.5%) 10 (30.3%) p=0.445 
Prior CABG 5 (15.2%) 4 (12.5%) 6 (18.2%) p=0.938 
Cardiac catheterization lab     
ACS on presentation 9 (27.3%) 7 (21.9%) 9 (27.3%) p=0.845 
Presence of collateral 8 (24.2%) 5 (15.6%) 7 (21.2%) p=0.677 
Current obstructive 
ASCVDa 
24 (72.7%) 25 (78.1%) 19 (57.6%) p=0.178 
Stenosis in most severe 
vessel (%) 
90 (60-90) 80 (52.5-93.8) 70 (50-95) p=0.311 
 
BMI = body mass index, TIA = transient ischemic attack, PCI = percutaneous coronary intervention, 
CABG = coronary artery bypass graft, ACS = acute coronary syndrome 
 
Data presented as median (interquartile range) or count (proportion) 
 
aCurrent obstructive coronary artery disease (CAD) defined as ≥ 50% stenosis in the left main coronary 
artery or ≥ 70% stenosis in one or more of the non-left main coronary arteries 
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Supplemental Table 3: Analysis of clinical factors across 14,15-EET:DHET ratio tertiles in 
the ASCVD population 
 
Characteristic Low 14,15-
EET:DHET 
Ratio (N=33) 
Medium 14,15- 
EET:DHET 
Ratio (N=32) 
High 14,15-
EET:DHET 
Ratio (N=33) 
p-value 
Age (years) 65 (53-68.5) 62.5 (51.3-69.8) 68 (60-75) p=0.030 
         Age > 65 years old 16 (48.5%) 13 (40.6%) 19 (57.6%) p=0.390 
Female 13 (39.4%) 16 (50.0%) 12 (36.4%) p=0.507 
African American race 4 (12.1%) 5 (15.6%) 7 (21.2%) p=0.642 
BMI (kg/m2) 31.7 (25.8-
37.2) 
30.1 (27.8-37.5) 28.9 (26.4-
35.2) 
p=0.407 
Obese BMI ≥ 30.00 18 (54.6%) 16 (50.0%) 14 (42.4%) p=0.609 
Current/recent (<1 year) smoker 13 (39.4%) 8 (25.0%) 8 (24.2%) p=0.325 
Past medical history     
History of hypertension 28 (84.9%) 23 (71.9%) 27 (81.8%) p=0.409 
History of diabetes 13 (39.4%) 12 (37.5%) 10 (30.3%) p=0.716 
History of hyperlipidemia 27 (81.8%) 20 (62.5%) 20 (60.6%) p=0.109 
Current heart failure  5 (15.2%) 5 (15.6%) 4 (12.1%) p=0.938 
Previous myocardial 
infarction 
9 (27.3%) 6 (18.8%) 7 (21.2%) p=0.700 
Previous stroke or TIA  6 (18.2%) 4 (12.5%) 2 (6.1%) p=0.323 
Previous 
Revascularization 
20 (60.6%) 11 (34.4%) 17 (51.5%) p=0.097 
Prior PCI 16 (48.5%) 9 (28.1%) 12 (36.4%) p=0.233 
Prior CABG 6 (18.2%) 2 (6.3%) 7 (21.2%) p=0.205 
Cardiac catheterization lab     
ACS on presentation 7 (21.2%) 10 (31.3%) 8 (24.2%) p=0.640 
Presence of collateral 9 (27.3%) 8 (25.0%) 3 (9.1%) p=0.140 
Current obstructive 
ASCVDa 
23 (69.7%) 22 (68.8%) 23 (69.7%) p=0.996 
Stenosis in most severe 
vessel (%) 
80 (55-95) 72.5 (50-90) 80 (60-90) p=0.694 
 
BMI = body mass index, TIA = transient ischemic attack, PCI = percutaneous coronary intervention, 
CABG = coronary artery bypass graft, ACS = acute coronary syndrome 
 
Data presented as median (interquartile range) or count (proportion) 
 
aCurrent obstructive coronary artery disease (CAD) defined as ≥ 50% stenosis in the left main coronary 
artery or ≥ 70% stenosis in one or more of the non-left main coronary arteries 
 
 
